DDIT3 and diffuse large B-cell lymphoma: For example, systemic DLBCL of the MCD subtype have a robust response to BTKi,16 with 100% 5-year event free survival (PFS) in younger patients when treated with BTKi plus R-CHOP versus <50% with R-CHOP alone).